Navigation Links
Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
Date:8/19/2007

Company on Target to File Supplemental New Drug Application in the Fourth

Quarter

FRAZER, Pa., Aug. 16 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) today announced positive results from a 12-week, Phase 3 clinical trial of FENTORA(R) (fentanyl buccal tablet) [C-II] in patients with breakthrough pain associated with a broad range of chronic non-cancer pain conditions. The study achieved statistical significance on the primary endpoint. Results across the 12 weeks of treatment showed both statistically significant and clinically relevant outcomes for patients with breakthrough pain who were already receiving and who were tolerant to opioid therapy for their underlying persistent pain. FENTORA is approved only for the management of breakthrough pain in patients with cancer who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain.

"We are excited to complete our Phase 3 program with this third and final controlled study. These data show similar positive outcomes as those with FENTORA in treating breakthrough pain in opioid-tolerant patients with cancer, chronic neuropathic pain, and chronic low-back pain," said Dr. Lesley Russell, Executive Vice President, Worldwide Medical and Regulatory Operations. "We plan to submit these data to the Food and Drug Administration in the fourth quarter as part of our supplemental New Drug Application."

About the Study

The double-blind, placebo-controlled, variable dose Phase 3 trial included 148 patients. The primary endpoint was the Sum of Pain Intensity Differences from five to 60 minutes (SPID(60)) as assessed after 12 weeks of treatment. SPID(60) is a measure that assesses analgesic efficacy of a pain medication over the first 60 minutes after treatment. Patients treated with FENTORA showed a statistically significant improvement on the primary endpoint (p<0.0001) compared with placebo. FENTORA was general
'/>"/>

SOURCE Cephalon, Inc.

Copyright©2007 PR Newswire.

Page: 1 2 3 4 5

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle announces $80M renewable energy strategy
5. GE announces first installation of Discovery VCT
6. UWM announces winners of RGI awards
7. Third Wave announces two senior management appointments
8. Mirus announces new method for making antibodies
9. Merge announces sofware updates, upcoming acquisition
10. Small Tree announces ethernet solution for Apple Xserv G5
11. TEKLYNX International announces new RFID software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... Axovant Sciences Ltd. (NYSE:  AXON), a leading clinical-stage ... upcoming presentations at three investor conferences: , Wednesday, ... Conference in New York at the ... 2:00 PM at the BioCentury NewsMakers Conference in ... Conference Center , Thursday, September 17 at 9:30 AM ...
(Date:9/2/2015)... Research and Markets ... Jain PharmaBiotech,s new report "DNA Sequencing - ... This report briefly reviews basics of ... their applications. Current large and small sequencers are ... applications of sequencing are described including those for ...
(Date:9/2/2015)... Sep. 02, 2015 ... the addition of Jain PharmaBiotech,s new report ... their offering. This report follows the ... that can be objectively measured and evaluated as ... as well as pharmacological responses to a therapeutic ...
(Date:9/2/2015)... 2, 2015 Biovista Inc. is ... the 2015 BeHEARD science challenge, a global competition hosted ... researchers, access to the latest life science innovations and ... and pathway analytics capability to support Steven Laffoon ... the study of Niemann-Pick Disease Type A (NPA), a ...
Breaking Biology Technology:Axovant Sciences To Present At Upcoming Investor Conferences 2Axovant Sciences To Present At Upcoming Investor Conferences 3Global DNA Sequencing Technologies Report 2015: Profiles of 130 Companies Involved in Sequencing and their 140 Collaborations 2Updated 2015 Biomarkers Report - Latest Technologies, Markets and Companies Insights to 2024 with over 1,000 References 2Updated 2015 Biomarkers Report - Latest Technologies, Markets and Companies Insights to 2024 with over 1,000 References 3Biovista Sponsors Wylder Nation Foundation's Research on Acid Sphingomyelinase Deficiency 2
... 19 Abbott (NYSE:,ABT) will announce its 2008 third-quarter ... opens., The announcement will be followed by a ... Central time (9 a.m. Eastern), and will be,accessible through ... archived edition of the call will be,available after 11 ...
... China, Sept. 19 /Xinhua-PRNewswire-FirstCall/ --,China-Biotics, Inc. (OTC ... Chinese firm specializing in the manufacture,research, development, ... that at its 2008 Annual General Meeting ... the Company,s nominees to the,Board of Directors., ...
... Quarter 2008 Earnings Conference Call Tuesday, October 28, 2008, 5:00 ... p.m. U.S. EDT, FRAZER, Pa., Sept. ... quarter 2008 results for 5:00 p.m. EDT on Tuesday,October 28, 2008., ... October 28, 2008 Schedule, 4:10 p.m. EDT Q3 2008 results ...
Cached Biology Technology:China-Biotics, Inc. Announces Results of 2008 Annual General Meeting of Shareholders 2
(Date:9/2/2015)... FELTON, California , September 2, 2015 /PRNewswire/ ... with the security purpose implied in a system ... hand geometry, voice, signature, iris, vein, DNA and ... crimes has forced to develop such system which ... by username, password, PIN, Patterns and tokens are ...
(Date:8/26/2015)... India , August 26, 2015 ... Three, Four, and Five Factor), Application (Travel & Immigration, ... Geography - Global Forecast to 2020", published by MarketsandMarkets, ... Billion by 2020, growing at a CAGR of 17.7% ... Tables and 82 F igures spread through 169 ...
(Date:8/20/2015)... Aug. 20, 2015   Sensory, Inc ., ... the user experience and security of consumer electronics ... announced that its TrulySecure™ is the ... to be FIDO Certified™. The FIDO ... with the FIDO UAF (Universal Authentication Framework) 1.0 ...
Breaking Biology News(10 mins):Biometrics Technology Market is Expected to Reach $13.8 Billion by 2015: Hexa Research Inc. 2Biometrics Technology Market is Expected to Reach $13.8 Billion by 2015: Hexa Research Inc. 3Biometrics Technology Market is Expected to Reach $13.8 Billion by 2015: Hexa Research Inc. 4Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 2Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 3Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 4Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 5TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 2TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 3TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 4TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 5
... GAINESVILLE, Fla. --- The observation that males evolve more ... biologist Charles Darwin noted the majesty of a peacocks ... peahens. No matter the species, males apparently ramp ... eternal competition to win the best mates, a concept ...
... and groundwater as well as snow fields and glaciers ... life and human livelihoods. Continuous observations are crucial ... mankind and the environment and also to provide crucial ... and droughts. These tasks are routinely undertaken by the ...
... for North America, released online this week by the U.S. ... overwhelmed by human-caused emissions. North American sources release nearly ... mostly as carbon dioxide. Carbon sinks such as ... these current sinks may turn into new sources as climate ...
Cached Biology News:Simple reason helps males evolve more quickly 2Simple reason helps males evolve more quickly 3Space technology put into service for global water resources observations 2First-ever 'State of the Carbon Cycle Report' finds troubling imbalance 2
Troponin I (22B11)...
Microlite 1+ 1x12 Strip assembled, flat bottom; the ideal vessel for low signal luminescent reactions, offering medium binding with enhanced dynamic range, extra high reflectivity and minimal cross t...
Immulon 4 HBX 1x12 Strip, flat bottom; high binding extra surface with special resin and irradiation, offers maximum protein uptake....
... 0-10 psi precision pressure regulator and pressurized syringe ... Faster liquid-switching Steady flow rate Microinjecting ... Can be added to any new ... any third-party manufacturer, even homemade. Connect to house ...
Biology Products: